In the last trading session, 0.26 million Bluebird bio Inc (NASDAQ:BLUE) shares changed hands as the company’s beta touched 0.72. With the company’s per share price at $7.79 changed hands at $0.13 or 1.70% during last session, the market valuation stood at $77.68M. BLUE’s last price was a discount, traded about -392.94% off its 52-week high of $38.40. The share price had its 52-week low at $5.80, which suggests the last value was 25.55% up since then. When we look at Bluebird bio Inc’s average trading volume, we note the 10-day average is 0.64 million shares, with the 3-month average coming to 420.62K.
Analysts gave the Bluebird bio Inc (BLUE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.20. If we narrow down to specifics, the data shows that 1 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended BLUE as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Bluebird bio Inc’s EPS for the current quarter is expected to be -5.74.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bluebird bio Inc (NASDAQ:BLUE) trade information
Instantly BLUE was in green as seen at the end of in last trading. With action -10.93%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -71.05%, with the 5-day performance at -10.93% in the red. However, in the 30-day time frame, Bluebird bio Inc (NASDAQ:BLUE) is 14.11% up. Looking at the short shares, we see there were 47.71 million shares sold at short interest cover period of 9.53 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12.5, meaning bulls need an upside of 37.68% from its current market value. According to analyst projections, BLUE’s forecast low is 5 with 25 as the target high. To hit the forecast high, the stock’s price needs a -220.92% plunge from its current level, while the stock would need to tank 35.82% for it to hit the projected low.
Bluebird bio Inc (BLUE) estimates and forecasts
Data shows that the Bluebird bio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -55.96% over the past 6 months, a 30.03% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 144.55% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 26.08M. 6 analysts are of the opinion that Bluebird bio Inc’s revenue for the current quarter will be 37.72M. The company’s revenue for the corresponding quarters a year ago was 7.83M and 18.57M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 232.89%. The estimates for the next quarter sales put growth at 103.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28.98%. The 2024 estimates are for Bluebird bio Inc earnings to increase by 23.06%, but the outlook for the next 5-year period is at 45.80% per year.
BLUE Dividends
Bluebird bio Inc is expected to release its next quarterly earnings report in January.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.63% of Bluebird bio Inc shares while 43.69% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 43.96%. There are 43.69% institutions holding the Bluebird bio Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 14.1544% of the shares, roughly 15.44 million BLUE shares worth $15.2 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.4422% or 10.3 million shares worth $10.14 million as of 2024-06-30.
